Pharmafile Logo
Pharmafocus logo
Advanced Search

CAR T

Showing 15 posts of 31 posts found.

kymriah

NICE rejects CAR-T therapy Kymriah for DLBCL in adults

September 19, 2018
Research and Development CAR T, CAR-T, Kymriah, NICE, Novartis, leukaemia

The National Institute for health and Care Excellence (NICE) has rejected Novartis’ CAR-T therapy Kymriah for use in adults with …

News

Novartis’ CAR T therapy Kymriah to become available on the NHS

September 5, 2018
Research and Development CAR T, CAR-T, Gilead, Kymriah, NHS, Novartis

Novartis’ Kymriah is set to become the first CAR T therapy to become available on the NHS after it was …

News
novartis_mit_us

Novartis to create 450 new jobs at Aargau site after Kymriah thumbs up

August 29, 2018
Research and Development CAR T, CAR-T, Jobs, Kymriah, Novartis

Swiss multinational Novartis is set to create up to 450 new jobs following the investment of 90 million Swiss Francs …

News
european_commission_web

Novartis’ Kymriah & Gilead’s Yescarta become first EU-approved CAR T therapies

August 28, 2018
Manufacturing and Production, Sales and Marketing CAR T, CAR-T, Cancer, EU, Gilead, Kymriah, Novartis, UK, Yescarta, blood cancer, pharma

Almost one full year since the treatment was given a “historic” approval in the US, Novartis’ CAR T therapy Kymriah …

News
fighting_cancer

Looking to the future of oncology

April 9, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR T, CAR-T, Cancer, feature, oncology, pharma

The oncology field moves so quickly that it can be hard to keep track of the latest innovations. Ben Hargreaves …

Feature
handshake2

bluebird backs own CAR-T prospect, takes option to co-develop with Celgene

March 29, 2018
Sales and Marketing Bluebird Bio, CAR T, CAR-T, Celgene, biotech, drugs, pharma, pharmaceutical

Biotech companies showing faith in their own prospect drug candidates is not an unusual occurrence, some do it to extremes. …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

January 19, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, Boehringer, CAR T, CAR-T, Celgene, Kymriah, Merck KGaA, Novartis, Philippines, Sanofi, gilotrif, juno therapeutics, nestle, top ten

It’s Friday, so it’s time to bring you another run-down of the top ten most popular articles with Pharmafile.com’s readers …

News
novartis_outside_1

Novartis’ CAR T therapy Kymriah scores accelerated approval in both Europe and US

January 17, 2018
Research and Development, Sales and Marketing CAR T, CAR-T, EMA, Europe, FDA, Kymriah, Novartis, US, pharma

Following up last year’s ground-breaking news that CAR T therapy Kymriah had become the first such treatment to be approved …

News
autolus_-_martin-pule

Promising new CAR-T therapy able to target T-cell lymphoma

November 15, 2017
Research and Development Autolus, CAR T, CAR-T, biotech, drugs, pharma, pharmaceutical

The CAR-T space has progressed rapidly over the last few years, culminating in FDA approvals for Novartis and Gilead to …

News
_97604447_kymriah-product-shot-8

CAR-T is bringing true precision to the fight against cancer

November 1, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR T, CAR-T, Gilead, Kymriah, Novartis, Yescarta

Matt Fellows investigates how the first-ever CAR-T therapy approvals in the past months could mean the field of cancer treatment …

Feature
gilead-sciences

Gilead completes £11.9 billion Kite Pharma acquisition

October 5, 2017
Sales and Marketing CAR T, CAR-T, Gilead, Kite, acquisition, pharma, pharmaceuticals

Gilead has announced that it has completed its acquisition of Kite Pharma after the deal was announced on 28 August …

News

FDA halts trial after first CAR T-associated patient death

September 6, 2017
Research and Development CAR T, CAR-T, Cancer, FDA, cellectis, leukaemia, patient death, pharma, pharmaceutical

French clinical-stage biopharma firm Cellectis has received an order from the FDA to halt its study of CAR T therapy …

News
entrance_takeda_i020_v1

Takeda partners up to develop “next generation” CAR T solid tumour therapy

September 4, 2017
Research and Development, Sales and Marketing CAR T, CAR-T, Cancer, Noile-Immune, Takeda, pharma, pharmaceuticals

Takeda is set to partner with Noile-Immune Biotech in the development of a “next generation” chimeric antigen receptor T-cell (CAR …

News
800px-cancer_cells_1

New research reports first-ever response of central nervous tumour to CAR T therapy

August 29, 2017
Manufacturing and Production, Research and Development CAR T, CAR-T, Cancer, life sciences, lymphoma, medicine, pharma, pharmaceuticals

Researchers at a General Hospital in Massachusetts has reported what they claim is the first response of a nervous system …

News

Unprecedented CAR-T data shows 100% response rate

June 7, 2017
Research and Development ASCO, CAR T, CAR-T

Researchers celebrated a world-first at the American Society of Clinical Oncology conference, revealing data which showed that, in a study …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023